Ongoing work in our laboratory is aimed at characterising the relationship between peripheral-blood sCD163 levels and stroke-induced adaptive immune dysfunction, as CD163 may be therapeutically targetable as a means of rescuing adaptive immune responsiveness following stroke. This evidence concerns the gene CD163 and Stroke.